Rani Therapeutics Holdings (RANI) Assets Average (2021 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Assets Average of $55.2 million for Q1 2026, up 81.87% year-over-year from $30.4 million in Q1 2025, and up 60.7% quarter-over-quarter from $34.4 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Assets Average (2021 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Assets Average history runs 6 years deep, the most recent figure standing at $55.2 million for Q1 2026.
- In Q1 2026, Assets Average rose 81.87% year-over-year to $55.2 million; the TTM figure through Mar 2026 stood at $55.2 million (up 81.87% YoY), while the FY2025 annual figure was $47.6 million, up 0.75% from the prior year.
- Assets Average for Q1 2026 stood at $55.2 million, up from $34.4 million in the prior quarter.
- The five-year high for Assets Average was $119.8 million in Q1 2022, with the low at $13.5 million in Q3 2025.
- The 5-year median for Assets Average is $55.7 million (2024), against an average of $65.8 million.
- The sharpest annual moves came in 2025 and 2026: Assets Average tumbled 69.02% in 2025, then jumped 81.87% in 2026.
- Rani Therapeutics Holdings' Assets Average stood at $108.1 million in 2022, then tumbled by 40.64% to $64.2 million in 2023, then slumped by 37.54% to $40.1 million in 2024, then dropped by 14.24% to $34.4 million in 2025, then jumped by 60.7% to $55.2 million in 2026.
- Business Quant data shows RANI's Assets Average at $55.2 million in Q1 2026, $34.4 million in Q4 2025, and $13.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | 56.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.36 Mn |
| Mar 31, 2026 | 55.25 Mn |
| Dec 31, 2025 | 34.38 Mn |
| Sep 30, 2025 | 13.52 Mn |
| Jun 30, 2025 | 20.51 Mn |
| Mar 31, 2025 | 30.38 Mn |
| Dec 31, 2024 | 40.09 Mn |
| Sep 30, 2024 | 43.63 Mn |
| Jun 30, 2024 | 48.62 Mn |
| Mar 31, 2024 | 55.71 Mn |
| Dec 31, 2023 | 64.18 Mn |
| Sep 30, 2023 | 76.97 Mn |
| Jun 30, 2023 | 89.98 Mn |
| Mar 31, 2023 | 102.24 Mn |
| Dec 31, 2022 | 108.11 Mn |
| Sep 30, 2022 | 106.27 Mn |
| Jun 30, 2022 | 109.83 Mn |
| Mar 31, 2022 | 119.76 Mn |
| Dec 31, 2021 | 130.58 Mn |
| Sep 30, 2021 | 107.14 Mn |